{"id":"W4284884980","doi":"10.1016/j.ejca.2022.05.023","title":"Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Ono Pharmaceutical; Ignyta; Chugai Pharmaceutical; EMD Serono; Genentech; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Puma Biotechnology; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Mirati Therapeutics; National Medical Research Council; Kissei; GlaxoSmithKline; Novartis Institutes for BioMedical Research; Amgen; Dainippon Sumitomo Pharma; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Rash; Internal medicine; Adverse effect; Clinical endpoint; Maculopapular rash; Discontinuation; Brain metastasis; Lung cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Phases of clinical research; T790M; non-small cell lung cancer (NSCLC); Cancer; Surgery; Toxicity; Epidermal growth factor receptor; Metastasis; Gefitinib; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006073763,0.0002407322,0.0006322183,0.0001726605,0.0002495301,0.00004354316,0.0003234269,0.00001327462,0.0002540092],"category_scores_gemma":[0.00004169674,0.000183728,0.0001649252,0.0002724392,0.0000390408,0.0001244749,0.000113277,0.0001588698,0.000001676159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001076492,"about_ca_system_score_gemma":0.001068483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003591441,"about_ca_topic_score_gemma":0.00009911137,"domain_scores_codex":[0.9978147,0.0002532405,0.0009526648,0.0003010111,0.0003857731,0.0002926174],"domain_scores_gemma":[0.9977579,0.00009397582,0.001140431,0.0002933709,0.0004933174,0.0002210001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07966519,0.1668855,0.01783648,0.00057068,0.01416291,0.005959494,0.08943409,0.004004192,0.1568665,0.00003848816,0.05429747,0.410279],"study_design_scores_gemma":[0.517611,0.1425594,0.003294892,0.0008665528,0.01284915,0.0002188761,0.0127638,0.0009161202,0.03427135,0.00001888029,0.2739223,0.0007077518],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806321,0.00575243,0.0001871312,0.001566635,0.0009133438,0.002568533,0.001133748,0.00001379918,0.00723227],"genre_scores_gemma":[0.9924605,0.0003387972,0.000828898,0.0003081467,0.0004304344,0.0002085881,0.00002647807,0.00007750318,0.005320692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4379458,"threshold_uncertainty_score":0.7492208,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06437095391339918,"score_gpt":0.3997258231664293,"score_spread":0.3353548692530301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}